Comparative Pharmacology
Head-to-head clinical analysis: ACTIGALL versus CRENESSITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIGALL versus CRENESSITY.
ACTIGALL vs CRENESSITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallstone dissolution agent; reduces cholesterol saturation of bile by decreasing hepatic cholesterol secretion and increasing bile acid pool.
CRENESSITY is a selective antagonist of the C-C chemokine receptor type 5 (CCR5), blocking HIV-1 entry into cells by binding to CCR5 and preventing gp120 interaction.
300 mg orally twice daily, or 8-10 mg/kg/day divided into 2-3 doses.
300 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3–5 days, reflecting enterohepatic circulation and slow turnover of the bile acid pool.
Terminal elimination half-life approximately 20 hours, supporting once-daily dosing.
Primarily fecal (biliary excretion of unchanged drug and metabolites); renal excretion is minimal (<1% of dose as unchanged drug).
Primarily hepatobiliary excretion into feces; less than 5% excreted renally as unchanged drug.
Category C
Category C
Bile Acid
Bile Acid